Harvard Bioscience, Inc. · NASDAQ:HBIO
Harvard Bioscience — Investor Presentation (January 2026)
15 slides from Harvard Bioscience's investor presentation, January 2026

Slide 1: HBIO Investor Overview
NASDAQ: HBIO HBIO Investor Overview January 2026 HBio Confidential 1

Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Forward Looking Statements This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward- looking statements may be identified

Slide 3: Solid Operating Platform to Support Growth & Improved Profitability
Solid Operating Platform to Support Growth & Improved Profitability Leading global tools provider with wide range of pre-clinical workflows and applications in several growth markets Largest business unit (Preclinical) with #1 position in high demand animal telemetry tools market Leader in rap

Slide 4: HBio at a Glance
HBio at a Glance What does HBio do? Who does HBio serve? Cellular & Molecular Academic / Biotech / CRO / Preclinical Systems Americas | EMEA | APAC Technology (CMT) Research Pharma Gov. Data acquisition, processing, and Technologies and tools necessary regulatory report generation for for research,

Slide 5: 2025 Goals & Performance
2025 Goals & Performance Q3 results demonstrated operational progress, consistent execution, and tangible improvement in several key areas of our business Priorities for 2025: Maintain financial discipline and positive cash generation Accelerate product adoption across our core growth platforms

Slide 6: HBio Investment Highlights
HBio Investment Highlights 1 Broad portfolio serves as one stop shop Leading provider for academic research, DIVERSIFIED CUSTOMER / for customers CROs & biotech / pharma customers REVENUE MODEL Systems & Software 2 Leading reputation, with multiple High barrier competitive advantages innovative tech

Slide 7: Broad Portfolio Serves as One Stop Shop for Customers
Broad Portfolio Serves as One Stop Shop for Customers Leading provider of products across the drug development cycle, spanning research and discovery, bioproduction and preclinical testing Preclinical Systems Products New: SoHo Implantable Telemetry System Measurement of biopotentials in small lab a

Slide 8: Leading Reputation, with Multiple Competitive Advantages
Leading Reputation, with Multiple Competitive Advantages HBio’s approach is powered by a unique product portfolio across the drug development cycle that drive differentiation beyond the products themselves First Mover Advantage Sticky Revenue • First commercial in-vitro microelectrode array • Many p

Slide 9: Long Standing Relationships with Blue-Chip Customers
Long Standing Relationships with Blue-Chip Customers ACADEMIC CONTRACT RESEARCH BIOTECH, RESEARCH ORGANIZATIONS PHARMACEUTICAL Scientific Research labs primarily Preclinical studies to determine safety and Perform early discovery and then government & grant funded efficacy of new pharmaceutica

Slide 10: Strong Global Footprint
Strong Global Footprint HBio’s global infrastructure provides a strong platform for further investment and growth Manufactures and tests majority of products in principal facilities in the NEUROSCIENCE United States, Germany and Spain RESEARCH Barcelona, Spain Operations primarily involve CELLUL

Slide 11: Exciting New Product Introduction (NPI) Pipeline Provides Numerous High Growth Opportunities
Exciting New Product Introduction (NPI) Pipeline Provides Numerous High Growth Opportunities STRENGTHEN THE BASE: DELIVER > MARKET GROWTH SIGNIFICANT INVESTMENT MADE, GROWTH TO FOLLOW Bio-Production In-Vitro Organoid Apps PRECLINICAL CMT CMT - ORGANOIDS • Ponemah Enterprise Data Acquisition/Analysis

Slide 12: Strong Management Team
Strong Management Team Supported by highly experienced employee base with nearly a third holding MS / PhDs John Duke Mark Frost Ryan Wallace President & CEO Interim CFO and Treasurer Senior VP Global Sales 25+ years of experience 30 years of finance experience, 20 as CFO 15 years of sales experience

Slide 13: Non-GAAP Reconciliation Table
Non-GAAP Reconciliation Table 13

Slide 14: Non-GAAP Reconciliation Table
Non-GAAP Reconciliation Table (1) Other operating expenses for the three months ended March 31, 2025 includes $93 thousand of restructuring-related charges and $171 thousand of employee retention Three Months Ended Three Months Ended Three Months Ended tax credit fees compared to $472 thousand of em

Slide 15: 18
18
Source: company website
More decks from Harvard Bioscience, Inc.
Q3 2026 Earnings Presentation15 slides · Nov 10, 2026
Investor Presentation (November 2026)32 slides · Nov 10, 2026
Q2 2026 Earnings Presentation15 slides · Aug 11, 2026
Investor Presentation (August 2026)32 slides · August 2026
Investor Presentation (May 2026)31 slides · May 12, 2026
Q1 2026 Earnings Presentation13 slides · May 12, 2026